Immunogenicity bridging assays are specialized analytical tests designed to detect, confirm, and characterize anti-drug antibodies (ADAs) against therapeutic proteins, enabling robust comparison of immunogenicity profiles between biosimilars and reference products. Performed by accredited third-party laboratories under ISO/IEC 17025-aligned quality systems and current regulatory guidance, these assays play a decisive role in clinical submissions, biosimilar approval, and post-approval safety monitoring. This article provides a comprehensive overview of immunogenicity bridging assay principles, sample types, test items, analytical methods, and practical applications.
Technical Overview
Immunogenicity is the capacity of a biotherapeutic, such as a monoclonal antibody, recombinant protein, peptide, or fusion protein, to provoke an immune response in recipients. The most common manifestation is the production of anti-drug antibodies (ADAs), which may accelerate drug clearance, diminish efficacy, cross-react with endogenous proteins, or trigger hypersensitivity and infusion reactions. Because even highly humanized molecules can be immunogenic, regulatory authorities worldwide require a risk-based immunogenicity evaluation for essentially all biologics.
In laboratory practice, the term immunogenicity bridging carries two complementary meanings. First, it describes the bridging immunoassay format, in which the therapeutic molecule itself serves as both capture and detection reagent: a bivalent or multivalent ADA simultaneously binds the surface-immobilized drug and a labeled drug tracer, forming a detectable immune complex bridge. Second, it refers to immunogenicity bridging studies, meaning integrated analytical and clinical comparisons of ADA incidence between a biosimilar or test product and its reference innovator product, or across different clinical studies and manufacturing process versions, when a single head-to-head trial is not feasible. Both concepts are governed by internationally harmonized expectations, including ICH S6(R1), USP General Chapter 1106, and relevant ISO standards such as ISO 10993-20 for medical device immunotoxicology and ISO/IEC 17025 for laboratory competence.
A scientifically sound bridging strategy follows the tiered approach recommended in current regulatory guidance: screening (detection of binding ADAs), confirmation (specificity verification by competitive inhibition), titer determination (semi-quantification), and neutralizing antibody (NAb) characterization to assess functional impact. Each tier requires a validated method with statistically justified cut points and demonstrated sensitivity, precision, drug tolerance, and robustness.
Testing Samples
Human Serum and Plasma
Serum or plasma collected from clinical trial subjects is the primary matrix. Sampling schemes typically include pre-dose baseline, end-of-infusion, trough, and post-treatment time points to capture the dynamics of ADA formation and persistence. Samples are aliquoted and stored at -60 degrees Celsius or below to preserve antibody integrity.
Animal Serum from Preclinical Studies
Serum from toxicokinetic and pharmacokinetic studies in mice, rats, rabbits, dogs, cynomolgus monkeys, and other species is analyzed to interpret exposure data, identify anti-drug antibody formation in animals, and support species relevance assessment as required by ICH S6(R1).
High-Drug-Interference Matrices
Long half-life monoclonal antibodies often leave substantial circulating drug in patient samples, masking ADA detection. Such matrices require drug-tolerance enhancement strategies, most commonly acid dissociation pretreatment, before analysis in bridging formats.
Special Matrices and Study-Specific Populations
Additional matrices include serum from patients with pre-existing antibodies or rheumatoid factor, hemolyzed or lipemic samples, cerebrospinal fluid in neurology programs, ocular fluids for intraocular biologics, and serum collected during medical device immunotoxicology evaluations conducted under ISO 10993-20.
Testing Items
- Screening anti-drug antibody (ADA) detection, identifying potentially positive samples relative to a validated screening cut point.
- Confirmatory ADA testing, using competitive binding with excess unlabeled drug to confirm specificity and eliminate false positives.
- ADA titer and semi-quantification, based on serial dilution analysis expressing relative antibody concentration with a defined titer cut point.
- Neutralizing antibody (NAb) assays, employing cell-based or ligand-binding formats to measure functional neutralization of drug activity.
- Immunoglobulin isotyping and subclassing, differentiating IgG, IgM, IgA, and IgE responses, particularly for hypersensitivity risk evaluation.
- Cross-reactivity evaluation, assessing ADA binding to endogenous homologs or related therapeutic molecules.
- Cut point determination and assay validation, statistically establishing screening, confirmatory, and titer cut points and fully characterizing assay performance.
- Integrated incidence reporting, summarizing treatment-boosted versus transient responses, onset, peak titer, and persistence.
Testing Methods
Bridging Enzyme-Linked Immunosorbent Assay (ELISA)
The classic bridging format immobilizes the drug on a microplate and applies the same drug conjugated with an enzyme, commonly horseradish peroxidase. A bivalent ADA captures both reagents, and the colorimetric signal is proportional to the antibody present. The homogeneous same-molecule bridge design inherently favors detection of divalent antibodies and eliminates species-specific secondary antibodies, making the method universally applicable to human and animal matrices.
Bridging Electrochemiluminescence Immunoassay (ECLIA)
Electrochemiluminescence platforms use drug labeled with a ruthenium-based tracer together with biotinylated drug captured on a streptavidin-coated solid phase, generating signal at an electrode surface. ECLIA offers superior sensitivity, a broad dynamic range, low background, and improved drug tolerance, and has become the platform of choice for many monoclonal antibody programs.
Acid Dissociation and Drug-Tolerance Enhancement
Pretreatment with dilute acid or alternative dissociation chemistries releases ADAs from circulating drug-ADA immune complexes before analysis, markedly improving drug tolerance. The acid stability of the positive control and of the drug reagents is verified during method development.
Confirmatory, Titer, and Neutralization Tiers
Confirmed positivity is established by demonstrating signal inhibition, commonly at least 50 percent, upon addition of excess unlabeled drug. Titers are reported as the reciprocal of the highest dilution exceeding the titer cut point. NAbs are measured either in cell-based systems reflecting the drug mechanism of action, preferred for many growth factors and cytokines, or in competitive ligand-binding non-cell formats.
Method Validation Parameters
Following ICH S6(R1), USP General Chapter 1106 conventions, and ISO/IEC 17025-aligned quality systems, validated attributes typically include:
- Screening and confirmatory cut points derived from disease-state and healthy blank matrices with outlier evaluation and 95th percentile statistics.
- Assay sensitivity expressed as the lowest titer of a pooled high-titer positive control detected with 95 percent confidence.
- Specificity and selectivity across individual donor matrices.
- Intra-assay and inter-assay precision, system suitability controls, and stability under freeze-thaw, bench-top, and long-term frozen storage conditions.
- Drug tolerance, target interference, hook effect (prozone), dilutional linearity, and robustness.
Applications
- Biosimilar development, through comparative ADA incidence, titer, and NAb analysis between biosimilar and reference products to demonstrate no clinically meaningful difference in immunogenicity.
- Manufacturing process changes, using analytical and clinical bridging to show that scale-up, site transfer, or formulation changes do not alter the immunogenicity profile.
- Clinical program support, providing sample analysis for Phase I through Phase III trials, immunogenicity risk mitigation, and interpretation of altered PK/PD exposure.
- Regulatory submissions, supplying data packages supporting investigational applications and marketing authorization filings across major jurisdictions.
- Post-marketing surveillance, monitoring ADA incidence and rare delayed hypersensitivity or cross-neutralization events in real-world populations.
- Medical device immunotoxicology, evaluating humoral immune responses to device materials and leachables consistent with ISO 10993-20.
- Emerging modalities, covering antibody-drug conjugates, bispecifics, fusion proteins, gene therapy vectors, and peptide therapeutics.
FAQ
What is the difference between a bridging assay and a bridging study?
A bridging assay is an analytical test format in which ADAs are detected through simultaneous binding of immobilized drug and labeled drug. A bridging study is a broader clinical and analytical comparison of immunogenicity between two products, processes, or studies. Biosimilar programs typically rely on both: bridging assays generate the ADA data, and the bridging study design enables cross-comparison with the reference product.
Why can a single universal assay not detect all ADAs?
ADAs are heterogeneous polyclonal populations differing in affinity, isotype, and specificity. Low-affinity IgM responses, monovalent binding, and circulating drug interference can escape detection in any single format. A risk- and molecule-specific method development phase is therefore mandatory before validation.
How are cut points established?
Screening cut points are typically set at the 95th percentile of the blank signal distribution from a representative panel of individual donor matrices, commonly 30 to 50 lots, with outlier testing and, where needed, a floating cut point approach corrected by the negative control. Confirmatory cut points apply an inhibition threshold, and titer cut points follow analogous statistical logic.
What sample volume and shipping conditions are required?
Typical per-analyte requirements range from 100 to 300 microliters of serum or plasma per time point, depending on the platform and titration needs. Samples should be shipped frozen on dry ice with continuous temperature monitoring to preserve antibody stability.
How long do method development and validation take?
Development usually spans several weeks, depending on molecule properties and interference challenges. Full validation of screening, confirmatory, and titer assays typically requires an additional eight to twelve weeks, while cell-based NAb validation may extend further due to biological variability controls.
Which standards and guidelines apply?
Key references include ICH S6(R1) for biotechnology product safety evaluation, USP General Chapters 1106 and 1106.1 for immunoassay and NAb method design and validation, ISO 10993-20 for medical device immunotoxicology testing strategy, and ISO/IEC 17025 for laboratory management and technical competence. Regional immunogenicity guidance from major regulatory authorities further defines study design and reporting expectations.